Antigua and Barbuda vs Iran, Islamic Republic of: Protecting minority investors: Extent of shareholder rights index
Antigua and Barbuda
50
in 2019
Iran, Islamic Republic of
50
in 2019
Antigua and Barbuda rank
102nd
Iran, Islamic Republic of rank
102nd
Protecting minority investors: Extent of shareholder rights index over time
- Antigua and Barbuda
- Iran, Islamic Republic of
How they compare
Antigua and Barbuda currently reports 50 against 50 in Iran, Islamic Republic of, a difference of 0.
Across all 7 years both countries report, Iran, Islamic Republic of has been ahead every year.
Antigua and Barbuda ranks 102nd and Iran, Islamic Republic of ranks 102nd of 191 countries.
Frequently asked questions
- Which has higher protecting minority investors: extent of shareholder rights index, Antigua and Barbuda or Iran, Islamic Republic of?
- Antigua and Barbuda, at 50 against 50 in Iran, Islamic Republic of as of 2019.
- What is the difference in protecting minority investors: extent of shareholder rights index between Antigua and Barbuda and Iran, Islamic Republic of?
- 0, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Iran, Islamic Republic of?
- 7 years are reported by both, from 2013 to 2019.
- How do Antigua and Barbuda and Iran, Islamic Republic of rank globally for protecting minority investors: extent of shareholder rights index?
- Antigua and Barbuda ranks 102nd and Iran, Islamic Republic of ranks 102nd of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Extent of shareholder rights index (0-6) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for extent of shareholder rights index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.